Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex’s Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid

SILVER SPRING, Md., Aug 20, 2014 (GLOBE NEWSWIRE via COMTEX) Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development s (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex s unique cancer treatment can slow the accumulation of fluid, known as malignant ascites, in the abdomen that is characteristic of the growth of many abdominal tumors. Kenneth L. Waggoner, CEO and President of Nuvilex, stated, The start of these studies at TD2 is a banner day for Nuvilex. We are extremely gratified to have a prestigious organization such as TD2 performing these studies on our behalf. It should be noted that these studies represent the first time that any work, either preclinical or clinical, has been done in the United States with the Cell-in-a-Box cellulose-based live cell encapsulation technology that has such exc
http://bit.ly/1n9QFP3